by | Apr 24, 2024 | Publications
Future Oncol. 2024 Apr 23. doi: 10.2217/fon-2023-0954. Online ahead of print. ABSTRACT WHAT IS THIS SUMMARY ABOUT?: This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new...
by | Apr 24, 2024 | Publications
Exp Hematol Oncol. 2024 Apr 23;13(1):45. doi: 10.1186/s40164-024-00507-5. ABSTRACT Histone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category...
by | Apr 24, 2024 | Publications
Biomark Res. 2024 Apr 23;12(1):43. doi: 10.1186/s40364-024-00592-y. ABSTRACT BACKGROUND: Activation of CD28 on multiple myeloma (MM) plasma cells, by binding to CD80 and CD86 on dendritic cells, decreases proteasome subunit expression in the tumor cells and thereby...
by | Apr 24, 2024 | Publications
Photodermatol Photoimmunol Photomed. 2024 May;40(3):e12965. doi: 10.1111/phpp.12965. NO ABSTRACT PMID:38654582 | DOI:10.1111/phpp.12965
by | Apr 24, 2024 | Publications
Eur J Haematol. 2024 Apr 23. doi: 10.1111/ejh.14214. Online ahead of print. ABSTRACT OBJECTIVES: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of...
by | Apr 24, 2024 | Publications
Cancer Epidemiol Biomarkers Prev. 2024 Apr 24. doi: 10.1158/1055-9965.EPI-23-1598. Online ahead of print. ABSTRACT BACKGROUND: Certain hazardous air pollutants (HAPs) are known or suspected to pose immunological or cancer risk to humans, but evidence is limited from...